<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3535">
  <stage>Registered</stage>
  <submitdate>30/04/2012</submitdate>
  <approvaldate>30/04/2012</approvaldate>
  <nctid>NCT01589419</nctid>
  <trial_identification>
    <studytitle>A Clinical Study Conducted in Multiple Centers Evaluating Escalating Doses of Veliparib in Combination With Capecitabine and Radiation in Patients With Locally Advanced Rectal Cancer</studytitle>
    <scientifictitle>An Open-Label Phase 1b Study of the Safety and Tolerability of Veliparib in Combination With Capecitabine and Radiation in Subjects With Locally Advanced Rectal Cancer (LARC)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>M12-950</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Locally Advanced Rectal Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bowel - Back passage (rectum) or large bowel (colon)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - veliparib
Treatment: drugs - capecitabine
Treatment: other - radiation

Experimental: veliparib and capecitabine and radiation - Veliparib on days 1-7, capecitabine and radiation on days 1-5


Treatment: drugs: veliparib
see arm description

Treatment: drugs: capecitabine
see arm description

Treatment: other: radiation
see arm description

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Treatment: other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Determine the maximum tolerated dose (MTD) and/or establish the recommended phase two dose (RPTD)</outcome>
      <timepoint>From first study drug dose and at each weekly treatment visit until dose-limiting toxicities (DLT) observed or completion of dosing period (anticipated to be approximately 5 weeks).</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Assess the safety (number of participants with adverse events and types of adverse events observed)</outcome>
      <timepoint>From screening and ongoing at each weekly treatment visit through dosing period (anticipated to be approximately 5 weeks), prior to surgery and at the final visit.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Assess the tolerability (number of participants with adverse events and types of adverse events observed)</outcome>
      <timepoint>From first study drug dose and ongoing at each weekly treatment visit, through completion of dosing period (anticipated to be approximately 5 weeks).</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Assess the pharmacokinetic profile by area under the curve vs. dose of veliparib</outcome>
      <timepoint>Multiple measurements over time points (0, .5, 1, 2, 3, 4, 6 hours post dose) Day 1, Day 2 and at the pre-dose time point on Day 5 and week 2 visit.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Subject must be = 18 years of age

          -  All subjects must have newly diagnosed, histologically proven adenocarcinoma of the
             rectum

          -  All subjects must have an abdominal/pelvis computed tomography (CT ) scan or magnetic
             resonance imaging (MRI) confirming no evidence of distant metastases

          -  Distal border of tumor &lt; 12 cm from anal verge

          -  Subjects must have an Eastern Cooperative Oncology Group (ECOG) Performance Score of 0
             to 2

          -  No prior treatment for LARC however prior treatments for other cancers are acceptable
             as long as they are considered curative</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Subject is an unsuitable candidate for TME surgery

          -  Subject has received anticancer therapy

          -  Subject has received prior radiation therapy

          -  Subject has had major surgery within 28 days prior to the first dose of study drug

          -  History of gastric surgery, vagotomy, bowel resection or any surgical procedure that
             might interfere with gastrointestinal motility, pH or absorption</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>32</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/01/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Site Reference ID/Investigator# 67882 - East Melbourne</hospital>
    <postcode>3002 - East Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>AbbVie (prior sponsor, Abbott)</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>An open-label, Phase 1b, dose escalation study evaluating the safety and tolerability of the
      PARP inhibitor Veliparib in combination with capecitabine and radiation in subjects with
      locally advanced rectal cancer (LARC).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01589419</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Philip Komarnitsky, MD</name>
      <address>AbbVie</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>